projects:workgroups:kb-wg
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision Next revision Both sides next revision | ||
|
projects:workgroups:kb-wg [2016/05/11 18:08] rkboyce |
projects:workgroups:kb-wg [2018/02/28 15:21] rkboyce |
||
|---|---|---|---|
| Line 1: | Line 1: | ||
| - | ====== Knowledgebase (LAERTES) Workgroup ====== | + | ====== Pharmacovigilance evidence investigation Workgroup ====== |
| <WRAP box justify round> | <WRAP box justify round> | ||
| - | **Objective:** The objective of this workgroup (WG) is to establish an open-source standardized knowledge base for the effects of medical products and an efficient procedure for maintaining and expanding it. For a complete overview, please see the paper [[http://www.ncbi.nlm.nih.gov/pubmed/24985530|Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest]]. The WG's first contribution to OHDSI will be LAERTES (Largescale Adverse Effects Related to Treatment Evidence Standardization) -- a system that integrates numerous sources of evidence useful for investigating the association of drugs and health into a single system. The system will extend the OHDSI Standard Vocabulary and provide for summary and drill down evidence review use cases. The first release of LAERTES is schedule for April 2015 | + | **Objective:** The objective of this workgroup (WG) is to establish an open-source standardized knowledge base for the effects of medical products and an efficient procedure for maintaining and expanding it. For a complete overview, please see the paper [[http://www.ncbi.nlm.nih.gov/pubmed/24985530|Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest]]. In 2015/16 the WG contributed LAERTES (Largescale Adverse Effects Related to Treatment Evidence Standardization) -- a system that integrates several sources of evidence investigating the association of drugs and health into a single system. The first staging release of LAERTES occurred last year and is reported in https://jbiomedsem.biomedcentral.com/articles/10.1186/s13326-017-0115-3. |
| - | **Project Lead:** [[http://ohdsi.org/who-we-are/collaborators/richard-d-boyce-2/|Richard D. Boyce, PhD]] | + | One of the primary use cases for the WG has been the creation of negative controls. Members of the WG published a paper reporting on the accuracy of automated negative control generation using machine learning and the merged evidence base: http://dx.doi.org/10.1016/j.jbi.2016.12.005 |
| - | **Project Co-Lead:** [[http://ohdsi.org/who-we-are/collaborators/erica-voss/|Erica Voss, MPH]] | + | The current efforts of the WG are focused on improving the process of creating and maintaining the merged evidence base, providing better support in OHDSI tools for negative control generation, and developing user friendly methods for using the merged evidence base to investigate pharmacovigilance signals. Other use cases are also being discussed. The new merged evidence base is called the Common Evidence Model and is accessible by requesting data from the project leads. The WG plans to make the data accessible from the OHDSI Web API by April 2018 (see https://goo.gl/1m6NcB). |
| - | **Members:** | + | **Project Lead:** [[http://ohdsi.org/who-we-are/collaborators/erica-voss/|Erica Voss, MPH]] |
| - | See [[kb-wg#internal|Members List]] | + | **Project Co-Lead:** [[http://ohdsi.org/who-we-are/collaborators/richard-d-boyce-2/|Richard D. Boyce, PhD]] |
| + | |||
| + | |||
| + | **Members:** | ||
| **Start Date:** 6/10/2014 | **Start Date:** 6/10/2014 | ||
| - | **Repository:** [[https://github.com/OHDSI/KnowledgeBase]] | + | **Repository:** [[https://github.com/OHDSI/CommonEvidenceModel]] |
| - | **WG Minutes:** [[https://docs.google.com/document/d/1T3TlmtkCL0BCNMJAUY76h4EV2mapEMAclaRFgmY_zzE/edit?usp=drive_web|Knowledge Base WG Minutes]] | + | **WG Minutes:** [[https://docs.google.com/document/d/1T3TlmtkCL0BCNMJAUY76h4EV2mapEMAclaRFgmY_zzE/edit?usp=drive_web|WG Minutes]] |
| - | **WG Agendas:** [[http://forums.ohdsi.org/t/laertes-team-meeting-agenda/172|Knowledge Base WG Agendas]] | + | **WG Agendas:** [[http://forums.ohdsi.org/t/laertes-team-meeting-agenda/172| WG Agendas]] |
| - | </WRAP> | + | **Publications:** |
| + | E.A. Voss, R.D. Boyce, P.B. Ryan, J. van der Lei, P.R. Rijnbeek, M.J. Schuemie, Accuracy of an Automated Knowledge Base for Identifying Drug Adverse Reactions, Journal of Biomedical Informatics, Available online 16 December 2016, ISSN 1532-0464, http://dx.doi.org/10.1016/j.jbi.2016.12.005. | ||
| - | ==== Meetings (Telecon Info) ==== | + | Boyce, RD., Voss, E., Huser, V., Evans, L., Reich, C., Duke, JD., Tatonetti, NP., Lorberbaum, T., Dumontier, M., Hauben, M., Wallberg, M., Peng, L., Dempster, S., He, O., Sena, A., Koutkias, V., Natsiavas, P., Ryan, P. (Knowledge Base workgroup of the Observational Health Data Sciences and Informatics (OHDSI) collaborative). Large-scale adverse effects related to treatment evidence standardization (LAERTES): an open scalable system for linking pharmacovigilance evidence sources with clinical data. J Biomed Semantics. 2017 Mar 7;8(1):11. doi: 10.1186/s13326-017-0115-3. Available at: https://jbiomedsem.biomedcentral.com/articles/10.1186/s13326-017-0115-3. PubMed PMID: 28270198; PubMed Central PMCID: PMC5341176. |
| - | Schedule: Two meetings occur on a Once per month schedule: | + | Boyce. RD., Ryan. PB., Noren. N., et al., Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest. Drug Safety. 2014. Volume 37, Issue 8 (2014), Page 557-567. DOI: 10.1007/s40264-014-0189-0, PubMed PMID: 24985530. PMCID: PMC4134480. http://link.springer.com/article/10.1007%2Fs40264-014-0189-0 |
| - | * LAERTES Afternoon Meeting: Tuesday from 3-4pm Eastern every four weeks starting from May 31st 2016. | ||
| - | * LAERTES Morning Meeting: Thursday from 9-10am Eastern every four weeks starting from May 31st 2016. | ||
| - | Please join my meeting. | + | </WRAP> |
| - | https://global.gotomeeting.com/join/530277469 | + | |
| - | Use your microphone and speakers (VoIP) - a headset is recommended. | + | ==== Meetings (Telecon Info) ==== |
| - | | + | |
| - | Or, call in using your telephone: | + | Schedule: |
| | | ||
| - | United States: +1 (224) 501-3217 | + | - All team call once per month on the 4th Wednesday of each month at 9-10 Eastern. |
| - | Sweden: +46 (0) 853 527 836 | + | |
| - | + | ||
| - | Access Code: 530-277-469 | + | |
| - | + | ||
| - | === Discussions === | + | |
| - | Search for "LAERTES" on [[http://forums.ohdsi.org/]] | + | - Touch point call on the 2nd Wednesday of each month 9-10 Eastern |
| - | === GitHub Issues === | ||
| - | [[https://github.com/OHDSI/KnowledgeBase/issues]] | + | Please join my meeting from your computer, tablet or smartphone. |
| + | https://global.gotomeeting.com/join/530277469 | ||
| - | === Members List === | + | You can also dial in using your phone. |
| + | United States: +1 (224) 501-3217 | ||
| - | - Abraham G. Hartzema, PhD, University of Florida, Gainesville, FL | + | Access Code: 530-277-469 |
| - | - Christian Reich, MD, PhD, AstraZeneca, Waltham MA | + | More phone numbers |
| + | Canada: +1 (647) 497-9350 | ||
| + | France: +33 170 950 594 | ||
| + | Netherlands: +31 207 941 377 | ||
| + | Sweden: +46 853 527 836 | ||
| + | Switzerland: +41 225 4599 78 | ||
| + | United Kingdom: +44 330 221 0088 | ||
| - | - Christophe Lambert, PhD, University of New Mexico, Albuquerque, NM | ||
| - | - Erica A. Voss, MPH, Janssen Research and Development, Titusville, PA | + | === Discussions === |
| - | - Gianluca Trifirò, PhD, University of Messina, Messina, Italy & Erasmus University Medical Center, Rotterdam, Netherlands | + | Search for "LAERTES" on [[http://forums.ohdsi.org/]] |
| + | |||
| + | === GitHub Issues === | ||
| - | - J. Marc Overhage, MD, PhD, Siemens Healthcare, Malvern, PA | + | [[https://github.com/OHDSI/CommonEvidenceModel/issues]] |
| - | - Jon Duke, MD, Regenstrief Institute, Indianapolis IN | ||
| - | - Johan Ellenius, PhD, Uppsala Monitoring Centre, Uppsala, Sweden | + | === Active members List (add or delete your name if you see an omission or error) === |
| - | - Lee Evans, LTS Computing LLC, West Chester, PA | + | Erica A. Voss, Janssen Research & Development, LLC, Titusville, NJ, EVoss3@its.jnj.com |
| - | - Majid Rastegar-Mojarad, MS, Mayo Clinic, Rochester, MN | + | Richard D. Boyce, University of Pittsburgh, Pittsburgh, PA, rdb20@pitt.edu |
| - | - Mark Khayter, BS, Ephir, Boston, MA | + | Lee Evans, LTS Computing LLC, West Chester, PA, levans@ltscomputingllc.com |
| - | - Martijn J. Schuemie, PhD, Janssen Research and Development, Titusville, PA | + | Anthony G. Sena, Janssen Research & Development, LLC, Titusville, NJ, asena5@its.jnj.com |
| - | - Michel Dumontier, PhD, Stanford University, Stanford, CA | + | Vassilis Koutkias, Institute of Applied Biosciences, Center for Research & Technology Hellas, Thermi, Thessaloniki, Greece, vkoutkias@certh.gr |
| - | - Nicholas P. Tatonetti, PhD, Columbia University, New York, NY | + | Pantelis Natsiavas, Institute of Applied Biosciences, Center for Research & Technology Hellas, Thermi, Thessaloniki, Greece, pnatsiavas@certh.gr |
| - | - Niklas Noren, PhD, Uppsala Monitoring Centre, Uppsala, Sweden | + | Manfred Hauben, MD. MPH, Pfizer Inc, New York University Medical Center, New York, NY, manfred.hauben@pfizer.com |
| - | - Rave Harpaz, PhD, Stanford University, Palo Alto, CA | + | Patrick B. Ryan, Janssen Research & Development, LLC, Titusville, NJ, ryan@ohdsi.org |
| - | - Vojtech Huser, MD PhD, National Institutes of Health, Bethesda, MD | ||
projects/workgroups/kb-wg.txt · Last modified: 2018/09/18 13:14 by ericavoss
Page Tools
